FDA/ASRM safety pipeline for donor sperm & egg — infectious disease testing, genetic screening, and the 6-month quarantine gate
Before a single straw is frozen, a prospective gamete donor must clear a rigorous, federally regulated eligibility determination. Under FDA 21 CFR Part 1271 (Human Cells, Tissues, and Cellular and Tissue-Based Products), reproductive tissue banks must document medical and social history, physical examination, communicable disease testing, and — per ASRM practice guidelines — genetic and psychological screening before a donor is even provisionally accepted.
FDA guidance requires a documented interview — conducted within 7 days of the donation used for eligibility determination — covering personal medical history, family history of heritable disease, and behavioral risk factors for "relevant communicable disease agents and disease" (RCDAD). Screeners probe intravenous drug use, incarceration history, recent tattoos or piercings, sexual history and partner risk, and travel to regions with endemic malaria, Zika, or other vector-borne pathogens.
A focused physical examination follows, screening for signs of infection, high-risk anatomical findings, and general reproductive health. Any positive risk-factor response can result in indefinite deferral regardless of test results, because behavioral risk can precede detectable infection markers by weeks.
FDA defines RCDAD screening criteria specifically so that behavioral risk — not just a lab result — can independently disqualify a donor. A donor with recent high-risk exposure is deferred even if every test on the day of screening is negative, because the infection may not yet be detectable.
FDA-mandated donor eligibility testing must use an FDA-licensed, approved, or cleared donor-screening test, performed by a CLIA-certified laboratory, on a specimen collected at or near the time of donation. The panel targets the pathogens with the greatest risk of transmission through reproductive tissue.
ASRM and ACMG guidance recommend expanded carrier screening covering 100+ autosomal-recessive and X-linked conditions — cystic fibrosis, spinal muscular atrophy, fragile X syndrome, hemoglobinopathies (sickle cell, thalassemias), and pan-ethnic panels that go well beyond the older ethnicity-targeted approach. A karyotype or chromosomal microarray is often obtained as well. Donors found to be carriers of significant conditions are typically excluded or their carrier status is disclosed for recipient matching.
A licensed mental health professional independently evaluates every gamete donor: psychiatric history, current mental status, motivation for donating, understanding of the psychological and legal implications of donor conception, and capacity to give informed consent. This evaluation is required by ASRM practice committee guidelines even though it sits outside the FDA's communicable-disease mandate.
Genetic and psychological screening are professional-society (ASRM/ACMG) requirements layered on top of the FDA's legally binding infectious-disease eligibility rule — a donor can be FDA-eligible on infection grounds yet still be rejected by a bank's genetic or psychological criteria.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| HIV-1 / HIV-2 | Human immunodeficiency virus | Antibody (EIA) + HIV-1 nucleic acid test (NAT) | NAT shortens detectable window to ~10 days |
| HBV | Hepatitis B virus | HBsAg + anti-HBc antibody + HBV NAT | Anti-HBc catches occult/resolved infection |
| HCV | Hepatitis C virus | Antibody (EIA) + HCV NAT | NAT closes long antibody-only window (~70 d) |
| Syphilis | Treponema pallidum | Treponemal or non-treponemal serology | Long-standing standard STI screen |
| CMV | Cytomegalovirus | IgG / IgM serology | Informational — used for recipient matching, not automatic exclusion |
| GC / CT | Neisseria gonorrhoeae, Chlamydia trachomatis | Nucleic acid amplification (NAAT) from urethral/urine specimen | Detects asymptomatic genital infection |
| HTLV-I / II | Human T-lymphotropic virus | Antibody (EIA) | Required per FDA relevant-pathogen list |
| Zika risk screen | Zika virus | Travel/behavioral history deferral (no routine serology) | FDA manages risk via time-limited deferral, not testing |
Once a donor is provisionally accepted, sperm and egg donation diverge sharply in logistics. Sperm can be collected repeatedly over months and frozen into an inventory that waits patiently in liquid nitrogen. Oocytes are retrieved in a single time-critical surgical cycle and must be vitrified within hours — a biological asymmetry that shapes every downstream safety decision, including whether a quarantine hold is even practical.
A sperm donor typically provides samples 2–3 times per week over several months. Each ejaculate is analyzed for concentration, motility, and morphology, then mixed with a cryoprotectant medium and loaded into labeled 0.5 mL straws — each straw traceable to a specific donor and donation date. Straws are cooled in liquid nitrogen vapor before final plunge into liquid phase (-196°C), where metabolic activity effectively halts and samples can remain viable for decades.
Every straw entering the tank is logged into a quarantine inventory system: it is physically present in storage but administratively locked from distribution until the donor clears the 6-month retest described in Stage 3.
An egg donor undergoes controlled ovarian stimulation: 10–12 days of injectable gonadotropins to mature multiple follicles simultaneously, monitored by serial ultrasound and estradiol bloodwork. A trigger injection (hCG or GnRH agonist) induces final oocyte maturation, and 34–36 hours later a transvaginal ultrasound-guided needle aspirates the mature oocytes directly from the ovarian follicles under sedation.
Because oocytes are exquisitely vulnerable to ice-crystal damage and lose viability rapidly outside the body, they are vitrified — flash-frozen at cooling rates exceeding 10,000°C per minute using high-concentration cryoprotectant — within hours of retrieval, well before any repeat infectious disease testing could plausibly be completed on that cycle's specimen.
The asymmetry is not regulatory neglect — it is biology. A single donor produces dozens of interchangeable, individually indexed sperm straws over months; holding any one straw for 6 months costs almost nothing, since another was frozen last week and can substitute in the interim inventory pipeline. Oocytes are scarce (single digits to low teens per cycle), each retrieval is a unique surgical event, and repeated freeze-thaw cycling to "re-test and re-release" would materially degrade the fragile cohort.
Instead, egg donation relies on front-loading the safety burden: rigorous point-of-donation testing performed as close as practical to the retrieval date, so results are current at the moment of use, substituting testing rigor for the passage of time.
Sperm banking trades storage cost for time — cheap, redundant units sit in LN2 until the window period closes. Egg banking cannot spend time, so it spends testing precision instead: results must already be current the moment the oocytes are vitrified.
This is the single most distinctive safety feature of donor sperm banking. Under 21 CFR 1271.85, donor sperm must be quarantined — physically stored but administratively withheld from any clinical use — for a minimum of six months, after which the donor is recalled for a second infectious disease screen. Only a confirmed-negative retest unlocks the inventory frozen on day zero.
Every infectious disease test has a window period: the interval between exposure/infection and the point at which the pathogen or the body's response to it becomes reliably detectable. A donor infected two days before donation could test negative on every assay available that day — not because they are uninfected, but because the marker being measured has not yet risen above the detection threshold.
Modern nucleic acid testing (NAT) has shrunk these windows dramatically (HIV to roughly 10 days, versus 3–12 weeks for older antibody-only assays), but no test has a zero-day window. Because donor sperm can be banked and used months or years after collection, regulators chose to close the residual gap with time itself rather than relying on test sensitivity alone.
Every straw frozen from a given donation is tagged with the donor ID and collection date and entered into a quarantine hold status in the bank's inventory management system. None of that inventory — regardless of how many units exist — can be shipped, thawed for clinical use, or transferred to a recipient while quarantine status is active. The hold is enforced administratively (inventory system lockout) as well as physically (segregated tank inventory), and is auditable by FDA inspectors.
At or after the 6-month mark, the bank recalls the donor for a fresh blood draw and repeats the full infectious disease panel from Stage 1. The clock resets with every new donation: a donor who donates weekly effectively has a rolling 6-month-delayed inventory release, so the bank is always distributing sperm collected roughly half a year earlier from a donor who has since tested clean twice.
Because nucleic acid testing detects the virus itself (viral RNA/DNA) rather than waiting for an antibody response, it has pushed window periods down to roughly a third of legacy serology-only timelines. This has prompted debate over whether the 6-month quarantine standard — set when antibody testing was the norm — remains proportionate. Some clinical programs and regulatory bodies outside the U.S. have explored shortened hold periods when NAT is used consistently, but in the United States the 6-month minimum for anonymous donor sperm remains the FDA baseline, and most accredited banks treat it as a floor rather than a target to shorten.
The 6-month figure predates routine NAT testing. It persists today less because it is the mathematically minimal safe interval, and more because it provides a wide margin of safety, institutional consistency, and regulatory predictability across a testing landscape that keeps improving.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Day 0 | Collection & cryopreservation | Frozen, quarantine-locked | Straws indexed and entered into hold inventory |
| Day 1–14 | Baseline results finalized | Frozen, quarantine-locked | Day-of-donation panel confirmed negative |
| Day 15–179 | Active quarantine hold | Frozen, quarantine-locked | Window period closing; no distribution permitted |
| Day 180 | Mandatory donor retest | Frozen, pending release decision | Full infectious disease panel repeated on donor |
| Day 180+ | Release decision | Released or discarded | Negative retest unlocks inventory; reactive retest discards it |
The quarantine hold accomplishes nothing on its own — it only creates the interval in which a second, independent test can catch what the first one missed. At six months, the donor is recalled and the full infectious disease panel is repeated. This retest is the actual release gate: everything before it was preparation, everything after it is disposition.
Release requires two independent negative results bracketing the quarantine interval: the baseline panel from the day of donation, and the confirmatory retest at ≥6 months. This two-point design specifically targets the window-period scenario — an infection acquired just before donation should, by the retest date, be well past every assay's detection threshold and would show up as reactive.
Only when both timepoints are clean does the inventory system unlock that donor's day-0 straws for distribution. The gate is binary and inventory-wide: a single reactive marker on retest does not selectively fail one straw — it fails the entire batch of inventory frozen from that donor since the last clean retest, because every one of those units shares the same unresolved exposure window.
A reactive (positive) result at the 6-month retest triggers a cascade: the donor is immediately and permanently deferred from further donation, the entire quarantined inventory associated with that donor since their last confirmed-negative test is destroyed under biohazard protocol, and a lookback investigation is initiated to determine whether any earlier units from the same donor were released under an exception (e.g., a directed donation to a known partner) and, if so, to notify the receiving facility and monitor the recipient.
This is a rare but consequential event, and it is precisely the scenario the entire quarantine architecture exists to catch before any anonymous recipient is exposed.
The quarantine system is designed so that a false negative on day 0 is not the last line of defense — it is caught by an independent, time-delayed second test before any anonymous recipient ever receives the tissue.
Because oocytes cannot wait six months, there is no equivalent retest step for egg donors. Instead, the entire safety burden is compressed into precision at the front end: testing is scheduled as close as clinically practical to the retrieval date (commonly within 30 days), sometimes with a repeat screen shortly before the stimulation cycle begins, so results are maximally current at the moment of vitrification. This does not eliminate residual window-period risk — it minimizes it through timing rather than eliminating it through elapsed time.
Inventory that clears the release gate is shipped to fertility clinics and recipients under FDA "eligible donor" labeling, entering a tracked distribution chain that also monitors how many families ultimately use gametes from the same donor. Inventory that fails is destroyed. Both outcomes close the loop that began with a donor questionnaire months or years earlier.
Once released, each unit carries FDA-required labeling identifying it as tissue from a donor who has met eligibility determination requirements, along with donor ID, collection date, and testing summary. Fertility clinics and sperm/egg banks maintain distribution records tying every released unit to the recipient it was ultimately used by, satisfying FDA's traceability and recordkeeping mandate, which requires records be retained for at least 10 years (many banks retain them indefinitely given the lifelong relevance to donor-conceived offspring).
Because a single donor can, in principle, supply gametes to dozens of families, professional guidelines recommend capping distribution to limit both the statistical risk of unknowing consanguinity between donor-conceived half-siblings and the psychosocial impact of very large sibling groups. ASRM guidance suggests a working limit of roughly 25 births (families) per population area of about 800,000 — a recommendation, not a law, and individual banks set their own policies within or beyond it.
This contrasts with countries like the United Kingdom, where the HFEA enforces a statutory 10-family limit per donor. The U.S. has no federal cap; some states and some clinics have adopted stricter voluntary limits, and consumer DNA-testing databases have made the historical assumption of donor anonymity increasingly unreliable regardless of any registry.
The U.S. donor-conception system leans on professional-society recommendations rather than statute for family limits — the 25-family figure is guidance banks are expected to follow, not a number any regulator enforces directly.
Discarded inventory is destroyed as regulated biohazardous/medical waste, and the event is documented as part of the bank's biovigilance record — the same category of adverse-event tracking used for blood and tissue banking generally. FDA inspection of accredited reproductive tissue banks reviews these records specifically to confirm the quarantine-and-retest system is functioning as intended and that no inventory bypassed the release gate.
Taken end to end, the entire five-stage pipeline — recruitment screening, collection, quarantine, retesting, and final disposition — exists to convert a single point-in-time test result (which can be wrong due to biological timing alone) into a system-level guarantee that is robust to that individual failure mode.